GERMANTOWN, Md.--(BUSINESS WIRE)--Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it would be presenting four posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, in San Francisco, CA.
The posters to be presented by Avalon will describe program success against two of the most clinically relevant and historically “undruggable” pathways in cancer: Beta-catenin and c-Myc. The posters are titled:
